Market Overview:
Urothelial or transitional cell carcinoma is a malignant neoplasm occurring from the urothelium. The disease is the ninth most common malignancy globally, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for approximately 90% of all urinary cancer cases.
Market Size Growth Rate:
According to the DataM market research report, the global urothelial cancer drugs market size was valued at USD XX billion in 2021, it is projected to reach at USD XX billion by 2029, with growth at a CAGR of 21.2% over the forecast period 2022-2029.
The global urothelial cancer drugs market is expected to rise at a solid pace in the next couple of years with solid competition among players and the rising cases of malignant malady. Nimble players are already seen taking the collaboration route for developing therapies and drugs. This would likely make the global urothelial cancer drugs market crowded with new products in the next couple of years.
Market Drivers:
Some of the major factors bolstering the market growth are the emergence and popularity of targeted therapy and the rise in the incidence of urothelial cancer. Bladder cancer is the 10th most common malignancy globally, according to the GLOBOCAN 2020, and the most frequently occurred type of bladder cancer is urothelial carcinoma. In the study titled, ‘Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths,’ published in December 2019, about 79.3% of the bladder cancer patients were of transitional cell carcinoma. An additional 6% showed associated squamous features.
Additionally, the urothelial cancer drugs market will likely benefit from better therapies being approved by prominent drug regulatory organizations. In April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene to treat advanced/metastatic urothelial carcinoma. Several novel treatments are predicted to see approvals, further supporting the market’s growth.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/urothelial-cancer-drugs-market
Market Restraints:
Chemotherapy drugs kill cancer cells but also damages the normal body cells. This results in the various side effects for the patients. Among the most common side effects are bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, fatigue and skin disorders are one of the major factors hindering the market growth.
Market Opportunities:
The therapies used in the global urothelial cancer drugs market are chemotherapy, intravesical therapy, and preservation therapy. Among those, chemotherapy finds application in treating invasive cancer and reducing the rate at which it spreads. In chemotherapy, adjuvant and neoadjuvant chemotherapy currently generate most of the revenue in the market owing to an alarming rise in cases of bladder cancer and the rising uptake of chemotherapy to treat the same.
COVID-19 Impact Analysis:
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe, with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies and governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage. Thus, the pharmaceutical and biotechnology industry is expected to witness significant growth due to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to impact the urothelial cancer drug market significantly.
Recent Developments in the Industry:
- In June 2020, Pfizer received the United States Food and Drug Administration approval for BAVENCIO. It has been approved as a first-line maintenance treatment among patients suffering from advanced/metastatic urothelial carcinoma.
- In April 2020, UroGen Pharma received the United States Food and Drug Administration approval for mitomycin gel (Jelmyto), which has been indicated for the treatment of low-grade upper tract urothelial cancer.
Market Segmentation:
As per the research analysis, the global urothelial cancer drugs market is segmented by type into Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma. By treatment into Chemotherapy, Immunotherapy. By distribution channel the market is further segmented into Hospital Pharmacies, Specialty Clinics, Cancer Institutes, Ambulatory Surgical Centers.
- On the basis of treatment, the chemotherapy segment is estimated to grow at highest CAGR of XX% during the forecast period (2022-2029). Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in your body. Chemotherapy is most often used to treat cancer since cancer cells grow and multiply much more quickly than most cells in the body. Therefore, they are less efficient for aiding digestion in the stomach compared to plant-based urothelial cancer drugs. Many different chemotherapy drugs are available. Chemotherapy drugs can be used alone or in combination to treat a wide variety of cancers. Though chemotherapy is an effective way to treat many types of cancer, chemotherapy treatment also carries a risk of side effects. Some chemotherapy side effects are mild and treatable, while others can cause serious complications. While chemotherapy has been proven to effectively attack cancer cells, it can cause serious side effects that can severely impact your quality of life. Chemotherapy is also used to prepare you for other treatments. It could be used to shrink a tumor so it can be surgically removed or to prepare you for radiation therapy.
- Based on distribution channel, hospital pharmacies segment accounted for the largest market share of around XX% in 2020 and expected to grow at a CAGR of XX% during the forecast period (2022-2029). Due to increased preference for the patients owing to the prevalence of urothelial cancer cases in recent years. Furthermore, increased access to specialty care products, pathological products, and clinical examinations, diagnosis of the cancer ailments at a single premise are best possible in hospitals indicate an exponential growth of the segment.
Geographical Classification:
The global urothelial cancer drugs market is segmented into major countries including North America, Europe, South America, Asia Pacific, and Middle East and Africa.
North America Urothelial Cancer Drugs Market:
North America at present is a prominent contributor to revenue in the urothelial cancer drugs market. Though the market in the region is somewhat saturated and would likely rise at a slow pace in the next couple of years, it would still retain its key position. This is because of the exhaustive research on developing targeted therapies by well-established vendors domiciled in the region. Some of those are Merck and Pfizer. The U.S. is said to be mainly powering the growth in the North America urothelial cancer drugs market.
The Asia-Pacific blood cancer drugs market was valued USD XX million in 2020 and is estimated to reach USD XX million by 2028. In APAC region, China offers a strong opportunity for market expansion. Factors such as high unmet clinical needs and the presence of a large target population are expected to propel the market in this region. Several local players are currently evaluating products as second/third-line treatments in Phase II trials and are well-positioned to be launched in the China market in the upcoming years.
Competitive Analysis:
The global urothelial cancer drugs market is highly competitive with the presence of major players. In the Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase their market share. The market is expected to grow increasingly crowded with several product launches during the forecast period.
Major Companies:
Some of the major key players in the market are Novartis AG, GlaxoSmithKline, Genentech, Bristol-Myers Squibb, Sanofi S.A., Eisai Co., Ltd., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., UroGen Pharma Ltd., Immunomedics, Inc., and others.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regards to the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
- Visualize the composition of the global urothelial cancer drugs market segmentation by type, treatment, distributional channel, and regions highlighting the key commercial assets and players.
- By Type: Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma
- By Treatment: Chemotherapy, Immunotherapy
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Cancer Institutes, Ambulatory Surgical Centers
- By Region: North America, South America, Europe, Asia Pacific and Middle East and Africa
- Identify commercial opportunities in the global urothelial cancer drugs market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as, porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis, reimbursement analysis and unmet needs etc.
- Excel data sheet with thousands of data points of global urothelial cancer drugs market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
- The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.
Trending Reports
Hashimoto’s Thyroiditis Drug Market
Pneumoconiosis Treatment Market
About Us:
DataM Intelligence 4Market Research is a market intelligence platform which gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed and food & beverages among others. Our platform has Insights on markets that uncover latest market research data that’s distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market by providing a complete view of the market with statistical forecasts. Our strategy centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.